Louisiana has proposed a “subscription-based payment model" for hepatitis C drugs it hopes can benefit the state and drugmakers alike. https://www.fiercepharma.com/pharma/louisiana-seeking-comments-netflix-model-for-hep-c-drugs
Discontinues its new-generation treatments but Zepatier is still making headway http://www.pmlive.com/pharma_news/merck_pulls_out_of_hepatitis_c_r_and_d_as_market_shrinks_1206662
Vosevi is aimed at tough to treat patients.
The post Gilead’s latest hep C combo approved in US appeared first on Pharmaphorum. https://pharmaphorum.com/news/gileads-latest-hep-c-combo-approved-us/
AbbVie’s hepatitis C drug granted early access in UK
The post AbbVie’s 8-week hepatitis C drug granted early access in UK appeared first on Pharmaphorum. https://pharmaphorum.com/news/abbvies-hepatitis-c-drug-granted-early-access-uk/
NewsThe Japanese MHLW designates priority review to certain medicines based on the clinical usefulness of the treatment and severity of the disease. Topics: Drug Pipeline http://www.dddmag.com/news/2017/03/japan-grants-priority-review-abbvies-investigational-regimen-all-major-hcv-genotypes
The European Medicines Agency (EMA) has validated and is assessing Gilead Sciences’ Marketing Authorization Application (MAA) for the investigational, once-daily, single tablet regimen of sofosbuvir 400 mg, velpatasvir 100 mg and voxilaprevir 100 mg (SOF/VEL/VOX) for the treatment of chronic hepatitis C virus (HCV)-infected patients. http://processandproduction.pharmaceutical-business-review.com/news/ema-validates-gileads-chronic-hepatitis-c-regimen-230117-5721592
AT THE LIVER MEETING 2016 BOSTON (FRONTLINE MEDICAL NEWS) – When given with ribavirin, a fixed-dose combination of sofosbuvir/velpatasvir (Epclusa) achieved a sustained viral response at 12 weeks (SVR-12) in 94% of decompensated cirrhotic patients with hepatitis C virus (HCV) genotypes 1-6 infection, according to Zobair M. Younossi, MD. Patients with and without cirrhosis also […] https://www.pm360online.com/sofosbuvirvelpatasvir-improved-patient-reported-outcomes-knocked-out-hcv-genotypes-1-6/
NICE has issued provisional guidance recommending the use of Gilead Sciences’ Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg) for the treatment of adult chronic hepatitis C genotype 1-6 patients in England and Wales.
This is the third sofosbuvir-based treatment to be recommended by NICE for treatment of the disease. Hepatitis C, if untreated, can cause serious liver damage and potentially life-threatening complications such as liver cancer.
read more http://www.pharmafile.com/news/509122/provisional-nice-recommendation-gilead-s-hepatitis-c-treatment
J&J, Achillion aim for best-in-class with early HCV data
Fri, 09/09/2016 – 10:07